How KYMRIAH May Help

Relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) treatment, individualized just for you

KYMRIAH^® (tisagenlecleucel) was originally studied in a global clinical trial of children and young adults with relapsed or refractory B-cell ALL, with many achieving an early and lasting remission. While many patients have been successfully treated with KYMRIAH, not all patients will respond the same way.

Refractory, your cancer did not respond to treatment; Relapsed, your cancer has returned; Remission, the signs of your cancer have disappeared or else your disease is under control. It does not necessarily mean a cure.

What are the long-term results?

Since KYMRIAH was approved, patients from the clinical trial have been followed to see how well they do over the course of years. A long-term follow-up of patients in the clinical trial was done at 24 months from the date of infusion of KYMRIAH.

Next: What to Expect With KYMRIAH >